A phase Ⅱ prospective trial of photobiomodulation therapy in limiting oral mucositis in the treatment of locally advanced head and neck cancer patients
Janielle Taylor(University of Pittsburgh), David A. Clump(West Virginia University), Khalil Baddour(University of Pittsburgh), Umamaheswar Duvvuri(City University of New York), Karen D. Holeva(UPMC Health System), Uzoma K. Iheagwara(UPMC Health System), Shaum Sridharan(University of Pittsburgh), Leila J. Mady(University of Pittsburgh Medical Center), Jonas T. Johnson(University of Pittsburgh), Robert L. Ferris(University of Pittsburgh), Seungwon Kim(UPMC Hillman Cancer Center), Mark Kubik(University of Pittsburgh), Vikram Gorantla(UPMC Hillman Cancer Center), Annette Quinn(UPMC Health System), Shuyan Zhai(Johns Hopkins University), James Ohr(University of Pittsburgh), Daniel P. Zandberg(UPMC Hillman Cancer Center)
Cited by 9
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590